CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications.
The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
白细胞免疫球蛋白样受体B（LILRB）蛋白具有跨膜结构及经典免疫受体酪氨酸抑制基序（ITIM）信号，在维持免疫稳态中发挥关键作用，并参与多种疾病的发病机制。本综述聚焦LILRB家族在血液系统恶性肿瘤中的复杂作用。这些受体已成为白血病、淋巴瘤和骨髓瘤的重要诊断及预后生物标志物。除预后意义外，LILRB还积极塑造免疫微环境，并直接影响血液系统恶性肿瘤的发病机制。此外，将LILRB确立为潜在治疗靶点，为这些疾病的精准医疗策略提供有前景的新方向。目前，多种靶向LILRB的疗法正处于临床前和临床试验阶段。本综述强调LILRB家族在血液系统恶性肿瘤中的多方面作用，突显其诊断和预后意义，以及其对疾病病理生理学的广泛影响和作为治疗靶点的价值。
The leukocyte immunoglobulin-like receptor B (LILRB) proteins, characterized by their transmembrane nature and canonical immunoreceptor tyrosine-based inhibitory motifs (ITIM) signaling, play a pivotal role in maintaining immune homeostasis and are implicated in the pathogenesis of various disease states.
This comprehensive review will focus on the intricate involvement of the LILRB family in hematologic malignancies. These receptors have emerged as valuable diagnostic and prognostic biomarkers in leukemia, lymphoma, and myeloma. Beyond their prognostic implications, LILRBs actively shape the immune microenvironment and directly influence the disease pathogenesis of hematologic malignancies.
Furthermore, their identification as potential therapeutic targets offer a promising avenue for precision medicine strategies in the treatment of these disorders. Currently, multiple LILRB directed therapies are in the preclinical and clinical trial pipelines. This review underscores the multifaceted role of the LILRB family in hematologic malignancies, highlighting their significance from diagnostic and prognostic perspectives to their broader impact on disease pathophysiology and as valuable therapeutic targets.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
